Johnson & Johnson (NYSE_JNJ) Gains FDA Approval For IMAAVY™ To Treat Myasthenia Gravis
2025-04-30 17-30
https://finance.yahoo.com/news/johnson-johnson-nyse-jnj-gains-173051884.html?.tsrc=rss
Unlock stock picks and a broker-level newsfeed that powers Wall Street.
Johnson & Johnson recently experienced a 3% price increase in the last quarter, a period during which significant developments occurred for the company. Notably, the FDA granted approval for IMAAVY, a new monoclonal antibody treatment for generalized myasthenia gravis, potentially strengthening J&J's portfolio in autoimmune conditions. Additionally, their Q1 earnings report highlighted a substantial increase in net income and an increased quarterly dividend, marking the 63rd consecutive rise. While overall market performance was positive, the company's specific advancements in product approvals and financial results likely provided added momentum to its share price.
Buy, Hold or Sell Johnson & Johnson? View our complete analysis and fair value estimate and you decide.
AI is about to change healthcare. These 25 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
Johnson & Johnson's recent FDA approval for IMAAVY could significantly bolster its product portfolio in autoimmune conditions, aligning well with the anticipated growth in their Innovative Medicine sector. This development, combined with their Q1 earnings increase and a steady dividend rise, underscores the company's efforts to mitigate challenges from drug exclusivity losses. With a five-year total return of 20%, the company has shown resilience, although it underperformed compared to the broader US market's 9.9% return over the last year. This contrasts with the US Pharmaceuticals industry, which saw a modest 0.5% return, illustrating Johnson & Johnson's competitive positioning within its industry.
Looking forward, these advancements may positively impact revenue and earnings forecasts, enhancing projections, particularly in immunology and oncology. However, these optimistic signs are tempered by possible revenue erosion from biosimilar competition and ongoing challenges like tariffs and litigation risks. The recent share price increase places J&J at a slight discount to the consensus analyst price target of US$169.38, highlighting a potential but not guaranteed upside. Investors should consider this context when evaluating whether the current price aligns with future growth assumptions and market positioning.
Examine Johnson & Johnson's past performance report to understand how it has performed in prior years.
 This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include NYSE:JNJ.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
We recently published a list of The Best and Worst Dow Stocks for the Next 12 Months. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against other best and worst dow stocks for the next 12 months. The Dow Jones Industrial Average (DJIA), or the Dow, […]
We recently published a list of Jim Cramer Reveals Details Of Trump’s Tariff Negotiations & Discusses 10 Stocks. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against other stocks that Jim Cramer discusses. In his recent appearance on CNBC’s Squawk on the Street, Jim Cramer commented […]
GSK reports mixed first-quarter 2025 results. Shares rise in pre-market after it reaffirms guidance and says it is "well positioned" to handle the U.S. tariffs.
The approval by the US regulator is based on data from the pivotal Vivacity-MG3 trial.
The partnership will combine ECARX’s tech with Qualcomm’s Snapdragon Cockpit Platforms to advance software-defined vehicles.
The technology giant plans to allocate $30 billion to mainframe and quantum computing production, as well as research and development.
When it comes to spending money on a vehicle, you've got to take the good news when you can. According to the most recent data, the average price of a new car in March 2025 was $48,641. That's a lot,...
Starbucks' latest earnings report showed a continued decline in US same-store sales as its business in China stabilized.
Buying a stock is easy, but buying the right stock without a good strategy is incredibly hard. Here are five top-performing stocks to buy now or put on a watchlist.
Learn about the rights, responsibilities, and requirements of being a cosigner for a loan.